<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Sci (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Med Sci (Basel)</journal-id><journal-id journal-id-type="publisher-id">medsci</journal-id><journal-title-group><journal-title>Medical Sciences</journal-title></journal-title-group><issn pub-type="epub">2076-3271</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407552</article-id><article-id pub-id-type="pmc">PMC12101364</article-id>
<article-id pub-id-type="doi">10.3390/medsci13020057</article-id><article-id pub-id-type="publisher-id">medsci-13-00057</article-id><article-categories><subj-group subj-group-type="heading"><subject>Systematic Review</subject></subj-group></article-categories><title-group><article-title>The Placebo Effect in Chronic Thromboembolic Pulmonary Hypertension Trials: A Systematic Review and Meta-Analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2520-5673</contrib-id><name><surname>Caldeira</surname><given-names>Daniel</given-names></name><xref rid="af1-medsci-13-00057" ref-type="aff">1</xref><xref rid="af2-medsci-13-00057" ref-type="aff">2</xref><xref rid="af3-medsci-13-00057" ref-type="aff">3</xref><xref rid="af4-medsci-13-00057" ref-type="aff">4</xref><xref rid="c1-medsci-13-00057" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0004-0277-7398</contrib-id><name><surname>Cazeiro</surname><given-names>Daniel In&#x000e1;cio</given-names></name><xref rid="af1-medsci-13-00057" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Pl&#x000e1;cido</surname><given-names>Rui</given-names></name><xref rid="af1-medsci-13-00057" ref-type="aff">1</xref><xref rid="af3-medsci-13-00057" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Ferreira</surname><given-names>Filipa</given-names></name><xref rid="af5-medsci-13-00057" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6719-2065</contrib-id><name><surname>Cal&#x000e9;</surname><given-names>Rita</given-names></name><xref rid="af5-medsci-13-00057" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8034-4529</contrib-id><name><surname>Pinto</surname><given-names>Fausto J.</given-names></name><xref rid="af1-medsci-13-00057" ref-type="aff">1</xref><xref rid="af3-medsci-13-00057" ref-type="aff">3</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Schulz</surname><given-names>Rainer</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-medsci-13-00057"><label>1</label>Servi&#x000e7;o de Cardiologia, Departamento de Cora&#x000e7;&#x000e3;o e Vasos, Centro Hospital Universit&#x000e1;rio Lisboa Norte (CHULN), Unidade Local de Saude Santa Maria, Centro Acad&#x000e9;mico de Medicina de Lisboa, 1649-035 Lisboa, Portugal<email>faustopinto@medicina.ulisboa.pt</email> (F.J.P.)</aff><aff id="af2-medsci-13-00057"><label>2</label>Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal</aff><aff id="af3-medsci-13-00057"><label>3</label>Centro Cardiovascular da Universidade de Lisboa (CCUL@RISE), Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal</aff><aff id="af4-medsci-13-00057"><label>4</label>Centro de Estudos de Medicina Baseada na Evid&#x000ea;ncia (CEMBE), Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal</aff><aff id="af5-medsci-13-00057"><label>5</label>Servi&#x000e7;o de Cardiologia, Hospital Garcia de Orta, 2805-267 Almada, Portugal; <email>filipamaferreira@hotmail.com</email> (F.F.); <email>ritacale@hotmail.com</email> (R.C.)</aff><author-notes><corresp id="c1-medsci-13-00057"><label>*</label>Correspondence: <email>dgcaldeira@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>57</elocation-id><history><date date-type="received"><day>21</day><month>2</month><year>2025</year></date><date date-type="rev-recd"><day>16</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>23</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Introduction:</bold> Placebo-controlled studies are crucial in clinical trials, but the placebo effect can vary across conditions. We aimed to assess the placebo effect in chronic thromboembolic pulmonary hypertension (CTEPH) trials. <bold>Methods:</bold> We conducted a systematic review and included randomized placebo-controlled trials investigating CTEPH interventions. Primary outcomes were the pre&#x02013;post changes in the 6 min walk test (6MWT) and quality of life in the placebo arms. Secondary outcomes included mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR), cardiac index, and NT-proBNP levels. Meta-analyses were performed using random-effects models. <bold>Results:</bold> Seven trials with 270 CTEPH patients in placebo arms were analyzed. The average 6MWT change was not significant (&#x02212;1.31 m; 95%CI &#x02212;12.49 to +9.79). Quality of life with EQ-5D was not significantly improved (&#x02212;0.04; 95%CI &#x02212;0.10 to +0.02). mPAP, PVR, cardiac index, and NT-proBNP also demonstrated non-significant changes with small magnitudes. <bold>Conclusions:</bold> The placebo effect in CTEPH trials was not statistically significant and had small magnitude but should not discourage the use of placebo-controlled trials where applicable and ethical.</p></abstract><kwd-group><kwd>chronic thromboembolic pulmonary hypertension (CTEPH)</kwd><kwd>placebo effect</kwd><kwd>clinical trials</kwd><kwd>systematic review</kwd><kwd>meta-analysis</kwd><kwd>6 min walk test (6MWT)</kwd><kwd>pulmonary vascular resistance (PVR)</kwd><kwd>EQ-5D</kwd><kwd>natriuretic peptide</kwd><kwd>pulmonary embolism</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-medsci-13-00057"><title>1. Introduction</title><p>Chronic thromboembolic pulmonary hypertension (CTEPH) is a progressive condition characterized by persistent obstruction of the pulmonary arteries due to unresolved thromboembolic material, leading to increased pulmonary vascular resistance and right heart failure. It represents a unique entity within the spectrum of pulmonary hypertension, differing from pulmonary arterial hypertension in its underlying pathophysiology, treatment approaches, and response to medical therapy [<xref rid="B1-medsci-13-00057" ref-type="bibr">1</xref>]. It represents a distinct form of pulmonary hypertension that is potentially curable with pulmonary endarterectomy (PEA); however, a substantial proportion of patients remain inoperable or experience persistent/recurrent pulmonary hypertension post-surgery [<xref rid="B2-medsci-13-00057" ref-type="bibr">2</xref>]. Pharmacologic therapy and balloon pulmonary angioplasty (BPA) have emerged as alternative strategies [<xref rid="B1-medsci-13-00057" ref-type="bibr">1</xref>], but the role of placebo or sham-controlled trials in this context remains a subject of debate.</p><p>The placebo effect, a well-documented phenomenon in clinical trials, can influence subjective outcomes such as exercise capacity and quality of life, potentially confounding treatment efficacy assessment [<xref rid="B3-medsci-13-00057" ref-type="bibr">3</xref>,<xref rid="B4-medsci-13-00057" ref-type="bibr">4</xref>,<xref rid="B5-medsci-13-00057" ref-type="bibr">5</xref>]. Moreover, placebo effects may be magnified in diseases with high symptom variability, such as CTEPH, where functional capacity is influenced by fluctuating hemodynamic and psychological factors.</p><p>In clinical trials, placebo-controlled studies are ubiquitous. The placebo effect is characterized by a perceived improvement resulting from the psychological effect of receiving care rather than the actual or no treatment. The success of placebo-controlled trials is primarily due to their double-blind design, which controls patient and assessor expectations, thereby controlling the placebo effect [<xref rid="B6-medsci-13-00057" ref-type="bibr">6</xref>].</p><p>Clinical trials for chronic thromboembolic pulmonary hypertension (CTEPH) have shown variability in the placebo effect, with some trials reporting significant improvements in exercise capacity and hemodynamic measurements in placebo groups [<xref rid="B7-medsci-13-00057" ref-type="bibr">7</xref>,<xref rid="B8-medsci-13-00057" ref-type="bibr">8</xref>].</p><p>Therefore, we aimed to assess the placebo effect in CTEPH trials evaluating subjective outcomes such as the distance in 6 min walking test (6MWT) and quality of life, as well as other objective measures within the placebo arms of trials. Using CTEPH as a model of disease, we expect that these data could be useful to assess the transversality of the placebo effect, to improve the understanding about the expectations of patients and investigators in CTEPH clinical trials.</p></sec><sec sec-type="methods" id="sec2-medsci-13-00057"><title>2. Methods</title><p>This systematic review with meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for healthcare intervention evaluations [<xref rid="B9-medsci-13-00057" ref-type="bibr">9</xref>]. The protocol is registered with doi:10.17605/OSF.IO/X35NW.</p><p>We included all published randomized placebo-controlled trials (RCTs) evaluating pharmacologic or interventional treatments for chronic thromboembolic pulmonary hypertension (CTEPH). Trials were eligible if they reported pre&#x02013;post data for six-minute walk test (6MWT) and/or quality of life (QoL) outcomes in placebo arms. Secondary outcomes included hemodynamic parameters, such as mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR), cardiac index, and NT-proBNP levels. We excluded observational studies, case reports, studies without a placebo arm, and perioperative interventions.</p><p>A thorough search was performed across MEDLINE and Cochrane Central Register of Controlled Trials (CENTRAL). We examined all the records retrieved from inception until February 2024. Our detailed search methodology is provided in the <xref rid="app1-medsci-13-00057" ref-type="app">Table S1</xref> using validated filters [<xref rid="B10-medsci-13-00057" ref-type="bibr">10</xref>]. Reference lists were also reviewed for relevant publications. The search was not restricted by language or date.</p><p>For study selection, a two-stage review process was employed: Firstly, an independent screening process of titles and abstracts was performed by two reviewers. Subsequently, the full texts of potentially relevant studies were examined for inclusion or exclusion. Any disagreements were discussed until a consensus was reached. The main reason for excluding key studies are depicted in <xref rid="app1-medsci-13-00057" ref-type="app">Table S2</xref>.</p><p>Data were extracted independently by two reviewers using a standardized data extraction form. Extracted variables included trial characteristics, participant demographics, intervention details, and outcome measures. Data were crosschecked for accuracy.</p><p>Risk of bias was assessed using the Cochrane Risk of Bias 2.0 tool, which evaluates sequence generation, allocation concealment, blinding, incomplete outcome data, and selective reporting [<xref rid="B11-medsci-13-00057" ref-type="bibr">11</xref>]. Each study was rated as having a low, high, or unclear risk of bias. Discrepancies were resolved by consensus.</p><p>Meta-analyses were conducted using STATA 17 software. The output included forest plots, showing both individual study outcomes and combined results. In the meta-analysis, we included continuous outcomes, reporting effect sizes as mean differences between baseline and follow-up for each trial arm, along with their corresponding 95% confidence intervals (CIs). We did not calculate standardized effect sizes (e.g., Cohen&#x02019;s <italic toggle="yes">d</italic>), as our goal was to synthesize absolute changes rather than relative ones. A random-effects model was employed to account for heterogeneity across studies [<xref rid="B12-medsci-13-00057" ref-type="bibr">12</xref>]. Heterogeneity was quantified using the I<sup>2</sup> percentage [<xref rid="B13-medsci-13-00057" ref-type="bibr">13</xref>], with values of &#x0003e;50% indicating substantial heterogeneity. Sensitivity analyses and meta-regressions were performed to assess the impact of potential confounders, including baseline characteristics and study duration.</p><p>As this study involved secondary analysis of meta-data of previously published trials, ethical approval was not required. The data used were extracted from publicly available sources.</p></sec><sec sec-type="results" id="sec3-medsci-13-00057"><title>3. Results</title><p>The search and evaluation of studies provided seven placebo-controlled trials with eligible data about 270 CTEPH patients allocated to the placebo arms (<xref rid="medsci-13-00057-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B7-medsci-13-00057" ref-type="bibr">7</xref>,<xref rid="B8-medsci-13-00057" ref-type="bibr">8</xref>,<xref rid="B14-medsci-13-00057" ref-type="bibr">14</xref>,<xref rid="B15-medsci-13-00057" ref-type="bibr">15</xref>,<xref rid="B16-medsci-13-00057" ref-type="bibr">16</xref>,<xref rid="B17-medsci-13-00057" ref-type="bibr">17</xref>,<xref rid="B18-medsci-13-00057" ref-type="bibr">18</xref>]. For the MERIT-1, we used the corrected and republished data [<xref rid="B8-medsci-13-00057" ref-type="bibr">8</xref>].</p><p>A total of seven randomized placebo-controlled trials were included in this systematic review [<xref rid="B7-medsci-13-00057" ref-type="bibr">7</xref>,<xref rid="B8-medsci-13-00057" ref-type="bibr">8</xref>,<xref rid="B14-medsci-13-00057" ref-type="bibr">14</xref>,<xref rid="B15-medsci-13-00057" ref-type="bibr">15</xref>,<xref rid="B16-medsci-13-00057" ref-type="bibr">16</xref>,<xref rid="B17-medsci-13-00057" ref-type="bibr">17</xref>,<xref rid="B18-medsci-13-00057" ref-type="bibr">18</xref>], comprising 279 patients allocated to placebo arms. The mean age across studies was 57 years. The median follow-up duration was 16 weeks (range: 12&#x02013;24 weeks) (<xref rid="medsci-13-00057-t001" ref-type="table">Table 1</xref>). The risk of bias was low in all randomized controlled trials due to their blinding methods that were appropriate, as well as other characteristics such as absence of significant missing data, adequate measurement of outcomes, and no selective reporting bias (<xref rid="app1-medsci-13-00057" ref-type="app">Figure S1</xref>).</p><p>Regarding exercise capacity, seven trials with data from 270 CTEPH patients showed that average 6MWT change in the placebo arm was not significant: &#x02013;1.31 m (95%CI &#x02212;12.49 to +9.79) (<xref rid="medsci-13-00057-f002" ref-type="fig">Figure 2</xref>). The quality of life measured through EQ-5D (range of values between &#x02212;1 and +1) in two trials with 126 patients showed a non-significant decrease in quality of life. (&#x02212;0.04; 95%CI &#x02212;0.10 to +0.02) (<xref rid="medsci-13-00057-f003" ref-type="fig">Figure 3</xref>).</p><p>Other objective outcomes did not show any significant results: mPAP and PVR showed a non-significant decrease, with a very small magnitude of &#x02212;0.89 mmHg (95%CI &#x02212;2.3 to 0.53) and &#x02212;16.66 dyn &#x000d7; s &#x000d7; cm<sup>&#x02212;5</sup> (95%CI &#x02212;61.88 to +28.56), respectively. Cardiac index and NT-proBNP also showed non-significant changes, with &#x02212;0.06 L/min/m<sup>2</sup> (95%CI &#x02212;0.16 to +0.04) and +34 ng/L (95%CI &#x02212;189.9 to +259), respectively.</p><p>Publication bias analysis was not significant in the Egger test and funnel plot appreciation (<xref rid="app1-medsci-13-00057" ref-type="app">Figure S2</xref>; <italic toggle="yes">p</italic>-value in Egger test = 0.44).</p><p>Sensitivity analyses and meta-regressions (for age, gender, and follow-up time) regarding the results of 6MWT did not change the results (<xref rid="app1-medsci-13-00057" ref-type="app">Figures S3&#x02013;S6; Table S3</xref>).</p></sec><sec sec-type="discussion" id="sec4-medsci-13-00057"><title>4. Discussion</title><p>This systematic review with meta-analysis provides a comprehensive assessment of the placebo effect in RCTs involving patients with CTEPH. The primary finding of our analysis suggests that the placebo effect in CTEPH trials is minimal, as demonstrated by the negligible changes in the 6MWT distance, quality of life, and key hemodynamic parameters. Taking the 6MWT as an example, the average decrease of 0.63 m in this evaluation, beyond negative, is far from the landmark 33 m improvement used to define the minimum important clinical difference in PAH patients [<xref rid="B19-medsci-13-00057" ref-type="bibr">19</xref>]. These findings hold important implications for the design and interpretation of clinical trials in this population.</p><p>The role of placebo in pulmonary hypertension trials has been previously explored in studies evaluating pulmonary arterial hypertension (PAH), which shares pathophysiological similarities with CTEPH. However, PAH is primarily a disease of the small pulmonary arteries, characterized by vasculopathy, endothelial dysfunction, and vascular remodeling, whereas CTEPH is predominantly a mechanical thrombotic obstructive disorder. These distinctions influence treatment approaches, with PAH typically managed using targeted vasodilatory therapies, while CTEPH may require additional surgical intervention or interventional procedures, such as pulmonary endarterectomy (PEA) or balloon pulmonary angioplasty (BPA).</p><p>A systematic review assessing the short-term impact of placebo therapy in PAH demonstrated that placebo-treated patients frequently experience clinical deterioration, including worsening of 6MWT and pulmonary hemodynamics [<xref rid="B20-medsci-13-00057" ref-type="bibr">20</xref>]. This contrasts with our findings, where no significant deterioration or improvement was observed in the placebo arms of CTEPH trials. One possible explanation for this discrepancy is the inherent difference in disease pathophysiology, with CTEPH being predominantly a mechanical obstruction disorder rather than a primary vasculopathy.</p><p>A key consideration in interpreting our findings is the potential for regression to the mean, a statistical phenomenon where extreme baseline values tend to shift toward the average over time. A recent analysis of PAH trials found that placebo effects in 6MWT are negligible when RTM is accounted for [<xref rid="B21-medsci-13-00057" ref-type="bibr">21</xref>]. This aligns with our results, reinforcing the notion that the observed changes in placebo groups of CTEPH trials are unlikely to be clinically meaningful. However, it is important to recognize that certain factors, such as patient expectations, trial design, and duration, may still influence placebo responses.</p><p>The findings from our study also align with those of previous reviews on the evolution of pharmacological interventions in CTEPH. The introduction of riociguat, the only currently approved pharmacologic therapy for CTEPH, was supported by the CHEST-1 trial, which demonstrated significant improvements in 6MWT and pulmonary hemodynamics compared with placebo [<xref rid="B22-medsci-13-00057" ref-type="bibr">22</xref>]. Notably, even in this well-conducted trial, the placebo group did not exhibit any substantial improvement in functional capacity, further supporting our conclusion that placebo responses in CTEPH were not statistically significant, and their magnitude was small. This suggests that the placebo/sham effect varies across conditions [<xref rid="B4-medsci-13-00057" ref-type="bibr">4</xref>,<xref rid="B5-medsci-13-00057" ref-type="bibr">5</xref>], and that in CTEPH, the physiological reserve might not be available due to the severity and limiting nature of the condition, as well as its evolutive nature.</p><p>We would like to emphasize that our data should not discourage the placebo-controlled trials despite the overall small magnitude of placebo effects in the setting of pulmonary hypertension/CTEPH, as there are still many areas where they can be applied [<xref rid="B23-medsci-13-00057" ref-type="bibr">23</xref>]. Actually, the ethical considerations surrounding the use of placebo in CTEPH trials are already being considered. Given the progressive nature of CTEPH, withholding active therapy in clinical trials could lead to a worsening of symptoms. The most common trial designs are active-controlled or placebo-controlled trials with novel treatments being tested as an add-on to standard therapy [<xref rid="B21-medsci-13-00057" ref-type="bibr">21</xref>]. Our data also suggest that future trials should account for the lack of clinically important placebo effect in the stopping rules of placebo-controlled trials to minimize patient exposure to placebo.</p><p>Recent advances in medical and interventional treatments for venous thromboembolic disease, along with their increasing implementation [<xref rid="B24-medsci-13-00057" ref-type="bibr">24</xref>,<xref rid="B25-medsci-13-00057" ref-type="bibr">25</xref>,<xref rid="B26-medsci-13-00057" ref-type="bibr">26</xref>], have raised expectations that the overall burden of CTEPH may decline. In particular, we anticipate that milder forms of CTEPH and/or recurrences following pulmonary vascular interventions may be associated with a more pronounced placebo effect than what was observed in the trials included in this systematic review and meta-analysis. Therefore, we underscore that the placebo effect observed in current trials may not be directly comparable to that in future CTEPH studies.</p><p>The limitations of our analysis include the relatively small sample size of included placebo arms and heterogeneity in trial designs. Moreover, while we focused on pre&#x02013;post changes within placebo groups, we did not compare these findings against active treatment arms in detail. Future studies should aim to expand the evidence base by incorporating larger datasets and exploring additional patient-centered outcomes.</p></sec><sec sec-type="conclusions" id="sec5-medsci-13-00057"><title>5. Conclusions</title><p>The placebo effect in CTEPH trials was not statistically significant and had a modest magnitude. Our results are informative for investigators and patients and despite this absence of relevant improvements in the placebo arms, it should not discourage the use of placebo-controlled trials where applicable and ethical.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-medsci-13-00057"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/medsci13020057/s1">https://www.mdpi.com/article/10.3390/medsci13020057/s1</uri>, Table S1: Search strings for OVID (MEDLINE and CENTRAL); Table S2: Studies excluded in full-text decision stage and reasons; Table S3: Results of univariate meta-regression regarding 6MWT. Figure S1: Risk of bias using RoB 2.0 for the outcome 6MWT; Figure S2: Funnel plot and Egger test result (<italic toggle="yes">p</italic>-value 0.44); Figure S3: Jackknife leave-one-out sensitivity analysis; Figure S4: Bubble plot of meta-regression of age impact in 6MWT in placebo arms; Figure S5: Bubble plot of meta-regression of % of female patients impact in 6MWT in placebo arms; Figure S6: Bubble plot of meta-regression of follow-up time impact in 6MWT in placebo arms.</p><supplementary-material id="medsci-13-00057-s001" position="float" content-type="local-data"><media xlink:href="medsci-13-00057-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization: D.C.; methodology: D.C.; software management: D.C.; validation: D.C., D.I.C., R.P., F.F., R.C. and F.J.P.; formal analysis: D.C.; Data retrieval and curation: D.I.C. and D.C.; writing&#x02014;original draft preparation: D.C.; critical appraisal, writing&#x02014;review and editing with substantial contributions: D.C., D.I.C., R.P., F.F., R.C. and F.J.P. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>D.C. has participated in educational meetings and/or attended a conferences or symposia (including travel, accommodation and/or hospitality), and/or received honoraria for consulting or lecturing from Amarin, Bayer, BIAL, Daiichi Sankyo, Menarini, outside the scope of this work. F.J.P received honoraria for consulting or lecturing from Boeh ringer-Ingelheim, Bayer Healthcare, Novartis, Menarini, Servier, Daichi Sankyo, Vifor International, Pfizer outside the scope of this work. The other authors do not have any conflicts of interest to disclose.</p></notes><ref-list><title>References</title><ref id="B1-medsci-13-00057"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Humbert</surname><given-names>M.</given-names></name>
<name><surname>Kovacs</surname><given-names>G.</given-names></name>
<name><surname>Hoeper</surname><given-names>M.M.</given-names></name>
<name><surname>Badagliacca</surname><given-names>R.</given-names></name>
<name><surname>Berger</surname><given-names>R.M.F.</given-names></name>
<name><surname>Brida</surname><given-names>M.</given-names></name>
<name><surname>Carlsen</surname><given-names>J.</given-names></name>
<name><surname>Coats</surname><given-names>A.J.S.</given-names></name>
<name><surname>Escribano-Subias</surname><given-names>P.</given-names></name>
<name><surname>Ferrari</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension</article-title><source>Eur. Heart J.</source><year>2022</year><volume>43</volume><fpage>3618</fpage><lpage>3731</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehac237</pub-id><pub-id pub-id-type="pmid">36017548</pub-id>
</element-citation></ref><ref id="B2-medsci-13-00057"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>N.H.</given-names></name>
<name><surname>D&#x02019;Armini</surname><given-names>A.M.</given-names></name>
<name><surname>Delcroix</surname><given-names>M.</given-names></name>
<name><surname>Ja&#x000ef;s</surname><given-names>X.</given-names></name>
<name><surname>Jevnikar</surname><given-names>M.</given-names></name>
<name><surname>Madani</surname><given-names>M.M.</given-names></name>
<name><surname>Matsubara</surname><given-names>H.</given-names></name>
<name><surname>Palazzini</surname><given-names>M.</given-names></name>
<name><surname>Wiedenroth</surname><given-names>C.B.</given-names></name>
<name><surname>Simonneau</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Chronic thromboembolic pulmonary disease</article-title><source>Eur. Respir. J.</source><year>2024</year><volume>64</volume><fpage>2401294</fpage><pub-id pub-id-type="doi">10.1183/13993003.01294-2024</pub-id><pub-id pub-id-type="pmid">39209473</pub-id>
</element-citation></ref><ref id="B3-medsci-13-00057"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaptchuk</surname><given-names>T.J.</given-names></name>
<name><surname>Stason</surname><given-names>W.B.</given-names></name>
<name><surname>Davis</surname><given-names>R.B.</given-names></name>
<name><surname>Legedza</surname><given-names>A.R.</given-names></name>
<name><surname>Schnyer</surname><given-names>R.N.</given-names></name>
<name><surname>Kerr</surname><given-names>C.E.</given-names></name>
<name><surname>Stone</surname><given-names>D.A.</given-names></name>
<name><surname>Nam</surname><given-names>B.H.</given-names></name>
<name><surname>Kirsch</surname><given-names>I.</given-names></name>
<name><surname>Goldman</surname><given-names>R.H.</given-names></name>
</person-group><article-title>Sham device v inert pill: Randomised controlled trial of two placebo treatments</article-title><source>BMJ</source><year>2006</year><volume>332</volume><fpage>391</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1136/bmj.38726.603310.55</pub-id><pub-id pub-id-type="pmid">16452103</pub-id>
</element-citation></ref><ref id="B4-medsci-13-00057"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fernandes</surname><given-names>A.</given-names></name>
<name><surname>David</surname><given-names>C.</given-names></name>
<name><surname>Pinto</surname><given-names>F.J.</given-names></name>
<name><surname>Costa</surname><given-names>J.</given-names></name>
<name><surname>Ferreira</surname><given-names>J.J.</given-names></name>
<name><surname>Caldeira</surname><given-names>D.</given-names></name>
</person-group><article-title>The effect of catheter-based sham renal denervation in hypertension: Systematic review and meta-analysis</article-title><source>BMC Cardiovasc. Disord.</source><year>2023</year><volume>23</volume><elocation-id>249</elocation-id><pub-id pub-id-type="doi">10.1186/s12872-023-03269-w</pub-id><pub-id pub-id-type="pmid">37173636</pub-id>
</element-citation></ref><ref id="B5-medsci-13-00057"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Palma</surname><given-names>C.</given-names></name>
<name><surname>David</surname><given-names>C.</given-names></name>
<name><surname>Fernandes</surname><given-names>R.M.</given-names></name>
<name><surname>Pinto</surname><given-names>F.J.</given-names></name>
<name><surname>Costa</surname><given-names>J.</given-names></name>
<name><surname>Ferreira</surname><given-names>J.J.</given-names></name>
<name><surname>Caldeira</surname><given-names>D.</given-names></name>
</person-group><article-title>The sham effect of invasive interventions in chronic coronary syndromes: A systematic review and meta-analysis</article-title><source>BMC Cardiovasc. Disord.</source><year>2022</year><volume>22</volume><elocation-id>223</elocation-id><pub-id pub-id-type="doi">10.1186/s12872-022-02658-x</pub-id><pub-id pub-id-type="pmid">35568808</pub-id>
</element-citation></ref><ref id="B6-medsci-13-00057"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaptchuk</surname><given-names>T.J.</given-names></name>
<name><surname>Miller</surname><given-names>F.G.</given-names></name>
</person-group><article-title>Placebo Effects in Medicine</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>373</volume><fpage>8</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1056/NEJMp1504023</pub-id><pub-id pub-id-type="pmid">26132938</pub-id>
</element-citation></ref><ref id="B7-medsci-13-00057"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghofrani</surname><given-names>H.-A.</given-names></name>
<name><surname>D&#x02019;Armini</surname><given-names>A.M.</given-names></name>
<name><surname>Grimminger</surname><given-names>F.</given-names></name>
<name><surname>Hoeper</surname><given-names>M.M.</given-names></name>
<name><surname>Jansa</surname><given-names>P.</given-names></name>
<name><surname>Kim</surname><given-names>N.H.</given-names></name>
<name><surname>Mayer</surname><given-names>E.</given-names></name>
<name><surname>Simonneau</surname><given-names>G.</given-names></name>
<name><surname>Wilkins</surname><given-names>M.R.</given-names></name>
<name><surname>Fritsch</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Riociguat for the treatment of chronic thromboembolic pulmonary hypertension</article-title><source>N. Engl. J. Med.</source><year>2013</year><volume>369</volume><fpage>319</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1209657</pub-id><pub-id pub-id-type="pmid">23883377</pub-id>
</element-citation></ref><ref id="B8-medsci-13-00057"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghofrani</surname><given-names>H.-A.</given-names></name>
<name><surname>Simonneau</surname><given-names>G.</given-names></name>
<name><surname>D&#x02019;Armini</surname><given-names>A.M.</given-names></name>
<name><surname>Fedullo</surname><given-names>P.</given-names></name>
<name><surname>Howard</surname><given-names>L.S.</given-names></name>
<name><surname>Ja&#x000ef;s</surname><given-names>X.</given-names></name>
<name><surname>Jenkins</surname><given-names>D.P.</given-names></name>
<name><surname>Jing</surname><given-names>Z.C.</given-names></name>
<name><surname>Madani</surname><given-names>M.M.</given-names></name>
<name><surname>Martin</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): Results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study</article-title><source>Lancet Respir. Med.</source><year>2024</year><volume>12</volume><fpage>e21</fpage><lpage>e30</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(24)00027-4</pub-id><pub-id pub-id-type="pmid">38548406</pub-id>
</element-citation></ref><ref id="B9-medsci-13-00057"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Page</surname><given-names>M.J.</given-names></name>
<name><surname>McKenzie</surname><given-names>J.E.</given-names></name>
<name><surname>Bossuyt</surname><given-names>P.M.</given-names></name>
<name><surname>Boutron</surname><given-names>I.</given-names></name>
<name><surname>Hoffmann</surname><given-names>T.C.</given-names></name>
<name><surname>Mulrow</surname><given-names>C.D.</given-names></name>
<name><surname>Shamseer</surname><given-names>L.</given-names></name>
<name><surname>Tetzlaff</surname><given-names>J.M.</given-names></name>
<name><surname>Akl</surname><given-names>E.A.</given-names></name>
<name><surname>Brennan</surname><given-names>S.E.</given-names></name>
<etal/>
</person-group><article-title>The PRISMA 2020 statement: An updated guideline for reporting systematic reviews</article-title><source>BMJ</source><year>2021</year><volume>372</volume><fpage>n71</fpage><pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id>
</element-citation></ref><ref id="B10-medsci-13-00057"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Glanville</surname><given-names>J.</given-names></name>
<name><surname>Kotas</surname><given-names>E.</given-names></name>
<name><surname>Featherstone</surname><given-names>R.</given-names></name>
<name><surname>Dooley</surname><given-names>G.</given-names></name>
</person-group><article-title>Which are the most sensitive search filters to identify randomized controlled trials in MEDLINE?</article-title><source>J. Med. Libr. Assoc.</source><year>2020</year><volume>108</volume><fpage>556</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.5195/jmla.2020.912</pub-id><pub-id pub-id-type="pmid">33013212</pub-id>
</element-citation></ref><ref id="B11-medsci-13-00057"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sterne</surname><given-names>J.</given-names></name>
<name><surname>Savovi&#x00107;</surname><given-names>J.</given-names></name>
<name><surname>Page</surname><given-names>M.</given-names></name>
<name><surname>Elbers</surname><given-names>R.G.</given-names></name>
<name><surname>Blencowe</surname><given-names>N.S.</given-names></name>
<name><surname>Boutron</surname><given-names>I.</given-names></name>
<name><surname>Cates</surname><given-names>C.J.</given-names></name>
<name><surname>Cheng</surname><given-names>H.Y.</given-names></name>
<name><surname>Corbett</surname><given-names>M.S.</given-names></name>
<name><surname>Eldridge</surname><given-names>S.M.</given-names></name>
<etal/>
</person-group><article-title>RoB 2: A revised tool for assessing risk of bias in randomised trials</article-title><source>BMJ</source><year>2019</year><volume>366</volume><fpage>l4898</fpage><pub-id pub-id-type="doi">10.1136/bmj.l4898</pub-id><pub-id pub-id-type="pmid">31462531</pub-id>
</element-citation></ref><ref id="B12-medsci-13-00057"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Higgins</surname><given-names>J.P.T.</given-names></name>
<name><surname>Thompson</surname><given-names>S.G.</given-names></name>
<name><surname>Spiegelhalter</surname><given-names>D.J.</given-names></name>
</person-group><article-title>A Re-Evaluation of Random-Effects Meta-Analysis</article-title><source>J. R. Stat. Soc. Ser. A Stat. Soc.</source><year>2009</year><volume>172</volume><fpage>137</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1111/j.1467-985X.2008.00552.x</pub-id><pub-id pub-id-type="pmid">19381330</pub-id>
</element-citation></ref><ref id="B13-medsci-13-00057"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Higgins</surname><given-names>J.P.T.</given-names></name>
<name><surname>Thompson</surname><given-names>S.G.</given-names></name>
<name><surname>Deeks</surname><given-names>J.J.</given-names></name>
<name><surname>Altman</surname><given-names>D.G.</given-names></name>
</person-group><article-title>Measuring inconsistency in meta-analyses</article-title><source>BMJ</source><year>2003</year><volume>327</volume><fpage>557</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1136/bmj.327.7414.557</pub-id><pub-id pub-id-type="pmid">12958120</pub-id>
</element-citation></ref><ref id="B14-medsci-13-00057"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ja&#x000ef;s</surname><given-names>X.</given-names></name>
<name><surname>D&#x02019;Armini</surname><given-names>A.M.</given-names></name>
<name><surname>Jansa</surname><given-names>P.</given-names></name>
<name><surname>Torbicki</surname><given-names>A.</given-names></name>
<name><surname>Delcroix</surname><given-names>M.</given-names></name>
<name><surname>Ghofrani</surname><given-names>H.A.</given-names></name>
<name><surname>Hoeper</surname><given-names>M.M.</given-names></name>
<name><surname>Lang</surname><given-names>I.M.</given-names></name>
<name><surname>Mayer</surname><given-names>E.</given-names></name>
<name><surname>Pepke-Zaba</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial</article-title><source>J. Am. Coll. Cardiol.</source><year>2008</year><volume>52</volume><fpage>2127</fpage><lpage>2134</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2008.08.059</pub-id><pub-id pub-id-type="pmid">19095129</pub-id>
</element-citation></ref><ref id="B15-medsci-13-00057"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suntharalingam</surname><given-names>J.</given-names></name>
<name><surname>Treacy</surname><given-names>C.M.</given-names></name>
<name><surname>Doughty</surname><given-names>N.J.</given-names></name>
<name><surname>Goldsmith</surname><given-names>K.</given-names></name>
<name><surname>Soon</surname><given-names>E.</given-names></name>
<name><surname>Toshner</surname><given-names>M.R.</given-names></name>
<name><surname>Sheares</surname><given-names>K.K.</given-names></name>
<name><surname>Hughes</surname><given-names>R.</given-names></name>
<name><surname>Morrell</surname><given-names>N.W.</given-names></name>
<name><surname>Pepke-Zaba</surname><given-names>J.</given-names></name>
</person-group><article-title>Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension</article-title><source>Chest</source><year>2008</year><volume>134</volume><fpage>229</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1378/chest.07-2681</pub-id><pub-id pub-id-type="pmid">18263674</pub-id>
</element-citation></ref><ref id="B16-medsci-13-00057"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Escribano-Subias</surname><given-names>P.</given-names></name>
<name><surname>Bendjenana</surname><given-names>H.</given-names></name>
<name><surname>Curtis</surname><given-names>P.S.</given-names></name>
<name><surname>Lang</surname><given-names>I.</given-names></name>
<name><surname>Vonk Noordegraaf</surname><given-names>A.</given-names></name>
</person-group><article-title>Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)</article-title><source>Pulm. Circ.</source><year>2019</year><volume>9</volume><fpage>2045894019846433</fpage><pub-id pub-id-type="doi">10.1177/2045894019846433</pub-id><pub-id pub-id-type="pmid">30957635</pub-id>
</element-citation></ref><ref id="B17-medsci-13-00057"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tanabe</surname><given-names>N.</given-names></name>
<name><surname>Fukuda</surname><given-names>K.</given-names></name>
<name><surname>Matsubara</surname><given-names>H.</given-names></name>
<name><surname>Nakanishi</surname><given-names>N.</given-names></name>
<name><surname>Tahara</surname><given-names>N.</given-names></name>
<name><surname>Ikeda</surname><given-names>S.</given-names></name>
<name><surname>Kishi</surname><given-names>T.</given-names></name>
<name><surname>Satoh</surname><given-names>T.</given-names></name>
<name><surname>Hirata</surname><given-names>K.-I.</given-names></name>
<name><surname>Inoue</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Selexipag for Chronic Thromboembolic Pulmonary Hypertension in Japanese Patients&#x02014;A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase II Study</article-title><source>Circ. J.</source><year>2020</year><volume>84</volume><fpage>1866</fpage><lpage>1874</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-20-0438</pub-id><pub-id pub-id-type="pmid">32879152</pub-id>
</element-citation></ref><ref id="B18-medsci-13-00057"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ogo</surname><given-names>T.</given-names></name>
<name><surname>Shimokawahara</surname><given-names>H.</given-names></name>
<name><surname>Kinoshita</surname><given-names>H.</given-names></name>
<name><surname>Sakao</surname><given-names>S.</given-names></name>
<name><surname>Abe</surname><given-names>K.</given-names></name>
<name><surname>Matoba</surname><given-names>S.</given-names></name>
<name><surname>Motoki</surname><given-names>H.</given-names></name>
<name><surname>Takama</surname><given-names>N.</given-names></name>
<name><surname>Ako</surname><given-names>J.</given-names></name>
<name><surname>Ikeda</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Selexipag for the treatment of chronic thromboembolic pulmonary hypertension</article-title><source>Eur. Respir. J.</source><year>2022</year><volume>60</volume><fpage>2101694</fpage><pub-id pub-id-type="doi">10.1183/13993003.01694-2021</pub-id><pub-id pub-id-type="pmid">34824052</pub-id>
</element-citation></ref><ref id="B19-medsci-13-00057"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moutchia</surname><given-names>J.</given-names></name>
<name><surname>McClelland</surname><given-names>R.L.</given-names></name>
<name><surname>Al-Naamani</surname><given-names>N.</given-names></name>
<name><surname>Appleby</surname><given-names>D.H.</given-names></name>
<name><surname>Blank</surname><given-names>K.</given-names></name>
<name><surname>Grinnan</surname><given-names>D.</given-names></name>
<name><surname>Holmes</surname><given-names>J.H.</given-names></name>
<name><surname>Mathai</surname><given-names>S.C.</given-names></name>
<name><surname>Minhas</surname><given-names>J.</given-names></name>
<name><surname>Ventetuolo</surname><given-names>C.E.</given-names></name>
<etal/>
</person-group><article-title>Minimal Clinically Important Difference in the 6-minute-walk Distance for Patients with Pulmonary Arterial Hypertension</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2023</year><volume>207</volume><fpage>1070</fpage><lpage>1079</lpage><pub-id pub-id-type="doi">10.1164/rccm.202208-1547OC</pub-id><pub-id pub-id-type="pmid">36629737</pub-id>
</element-citation></ref><ref id="B20-medsci-13-00057"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Helman</surname><given-names>D.L.</given-names></name>
<name><surname>Brown</surname><given-names>A.W.</given-names></name>
<name><surname>Jackson</surname><given-names>J.L.</given-names></name>
<name><surname>Shorr</surname><given-names>A.F.</given-names></name>
</person-group><article-title>Analyzing the Short-term Effect of Placebo Therapy in Pulmonary Arterial Hypertension</article-title><source>Chest</source><year>2007</year><volume>132</volume><fpage>764</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1378/chest.07-0236</pub-id><pub-id pub-id-type="pmid">17505027</pub-id>
</element-citation></ref><ref id="B21-medsci-13-00057"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anheyer</surname><given-names>D.</given-names></name>
<name><surname>Bugaj</surname><given-names>T.J.</given-names></name>
<name><surname>L&#x000fc;dtke</surname><given-names>R.</given-names></name>
<name><surname>Appelbaum</surname><given-names>S.</given-names></name>
<name><surname>Tr&#x000fc;bel</surname><given-names>H.</given-names></name>
<name><surname>Ostermann</surname><given-names>T.</given-names></name>
</person-group><article-title>No Placebo Effect beyond Regression to the Mean on the Six Minute Walk Test in Pulmonary Arterial Hypertension Trials</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>1069</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24021069</pub-id><pub-id pub-id-type="pmid">36674584</pub-id>
</element-citation></ref><ref id="B22-medsci-13-00057"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>N.H.</given-names></name>
<name><surname>Papamatheakis</surname><given-names>D.G.</given-names></name>
<name><surname>Fernandes</surname><given-names>T.M.</given-names></name>
</person-group><article-title>Evolution of randomized, controlled studies of medical therapy in chronic thromboembolic pulmonary hypertension</article-title><source>Pulm. Circ.</source><year>2021</year><volume>11</volume><fpage>20458940211007373</fpage><pub-id pub-id-type="doi">10.1177/20458940211007373</pub-id><pub-id pub-id-type="pmid">34104419</pub-id>
</element-citation></ref><ref id="B23-medsci-13-00057"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Caldeira</surname><given-names>D.</given-names></name>
<name><surname>Loureiro</surname><given-names>M.J.</given-names></name>
<name><surname>Costa</surname><given-names>J.</given-names></name>
<name><surname>Pinto</surname><given-names>F.J.</given-names></name>
<name><surname>Ferreira</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Oral anticoagulation for pulmonary arterial hypertension: Systematic review and meta-analysis</article-title><source>Can. J. Cardiol.</source><year>2014</year><volume>30</volume><fpage>879</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1016/j.cjca.2014.04.016</pub-id><pub-id pub-id-type="pmid">24986048</pub-id>
</element-citation></ref><ref id="B24-medsci-13-00057"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tanabe</surname><given-names>N.</given-names></name>
<name><surname>Ogo</surname><given-names>T.</given-names></name>
<name><surname>Hatano</surname><given-names>M.</given-names></name>
<name><surname>Kigawa</surname><given-names>A.</given-names></name>
<name><surname>Sunaya</surname><given-names>T.</given-names></name>
<name><surname>Sato</surname><given-names>S.</given-names></name>
</person-group><article-title>Safety and effectiveness of riociguat for chronic thromboembolic pulmonary hypertension in real-world clinical practice: Interim data from post-marketing surveillance in Japan</article-title><source>Pulm. Circ.</source><year>2020</year><volume>10</volume><fpage>2045894020938986</fpage><pub-id pub-id-type="doi">10.1177/2045894020938986</pub-id><pub-id pub-id-type="pmid">32754307</pub-id>
</element-citation></ref><ref id="B25-medsci-13-00057"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cal&#x000e9;</surname><given-names>R.</given-names></name>
<name><surname>Ferreira</surname><given-names>F.</given-names></name>
<name><surname>Pereira</surname><given-names>A.R.</given-names></name>
<name><surname>Saraiva</surname><given-names>C.</given-names></name>
<name><surname>Santos</surname><given-names>A.</given-names></name>
<name><surname>Alegria</surname><given-names>S.</given-names></name>
<name><surname>Repolho</surname><given-names>D.</given-names></name>
<name><surname>Vitorino</surname><given-names>S.</given-names></name>
<name><surname>Santos</surname><given-names>P.</given-names></name>
<name><surname>Morgado</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Balloon pulmonary angioplasty protocol in a Portuguese pulmonary hypertension expert center</article-title><source>Rev. Port. Cardiologia</source><year>2021</year><volume>40</volume><fpage>653</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1016/j.repc.2020.11.014</pub-id></element-citation></ref><ref id="B26-medsci-13-00057"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cal&#x000e9;</surname><given-names>R.</given-names></name>
<name><surname>Ferreira</surname><given-names>F.</given-names></name>
<name><surname>Pereira</surname><given-names>A.R.</given-names></name>
<name><surname>Repolho</surname><given-names>D.</given-names></name>
<name><surname>Sebaiti</surname><given-names>D.</given-names></name>
<name><surname>Alegria</surname><given-names>S.</given-names></name>
<name><surname>Vitorino</surname><given-names>S.</given-names></name>
<name><surname>Santos</surname><given-names>P.</given-names></name>
<name><surname>Pereira</surname><given-names>H.</given-names></name>
<name><surname>Brenot</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Safety and efficacy of balloon pulmonary angioplasty in a Portuguese pulmonary hypertension expert center</article-title><source>Rev. Port. Cardiol.</source><year>2021</year><volume>40</volume><fpage>727</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1016/j.repc.2020.10.016</pub-id><pub-id pub-id-type="pmid">34857110</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="medsci-13-00057-f001"><label>Figure 1</label><caption><p>Flowchart of studies selection.</p></caption><graphic xlink:href="medsci-13-00057-g001" position="float"/></fig><fig position="float" id="medsci-13-00057-f002"><label>Figure 2</label><caption><p>Forest plots of 6MWT and quality of life change in placebo arms. Blue squares with lines represent individual study effect sizes with 95% confidence intervals; square size reflects study weight. The green diamond indicates the pooled effect size and its 95% confidence interval. Studies included with their references: BENEFiT [<xref rid="B14-medsci-13-00057" ref-type="bibr">14</xref>]; Suntharalingam et al. [<xref rid="B15-medsci-13-00057" ref-type="bibr">15</xref>]; CHEST-1 [<xref rid="B7-medsci-13-00057" ref-type="bibr">7</xref>]; MERIT-1 [<xref rid="B8-medsci-13-00057" ref-type="bibr">8</xref>]; AMBER 1 [<xref rid="B16-medsci-13-00057" ref-type="bibr">16</xref>]; Tanabe et al. [<xref rid="B17-medsci-13-00057" ref-type="bibr">17</xref>]; Ogo et al. [<xref rid="B18-medsci-13-00057" ref-type="bibr">18</xref>].</p></caption><graphic xlink:href="medsci-13-00057-g002" position="float"/></fig><fig position="float" id="medsci-13-00057-f003"><label>Figure 3</label><caption><p>Forest plots of mPAP, PVR, cardiac index, and NT-proBNP change in placebo arms. Blue squares with lines represent individual study effect sizes with 95% confidence intervals; square size reflects study weight. The green diamond indicates the pooled effect size and its 95% confidence interval. Studies included with their references: BENEFiT [<xref rid="B14-medsci-13-00057" ref-type="bibr">14</xref>]; Suntharalingam et al. [<xref rid="B15-medsci-13-00057" ref-type="bibr">15</xref>]; CHEST-1 [<xref rid="B7-medsci-13-00057" ref-type="bibr">7</xref>]; MERIT-1 [<xref rid="B8-medsci-13-00057" ref-type="bibr">8</xref>]; AMBER 1 [<xref rid="B16-medsci-13-00057" ref-type="bibr">16</xref>]; Tanabe et al. [<xref rid="B17-medsci-13-00057" ref-type="bibr">17</xref>]; Ogo et al. [<xref rid="B18-medsci-13-00057" ref-type="bibr">18</xref>].</p></caption><graphic xlink:href="medsci-13-00057-g003" position="float"/></fig><table-wrap position="float" id="medsci-13-00057-t001"><object-id pub-id-type="pii">medsci-13-00057-t001_Table 1</object-id><label>Table 1</label><caption><p>Overall characteristics of included studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Trial</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N Placebo Arm</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Age (Mean/SD or Median/IQR)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">% Females</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">BMI</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Background PH Therapy</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PEA/BPA</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Follow-Up</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>BENEFiT [<xref rid="B14-medsci-13-00057" ref-type="bibr">14</xref>]</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">80</td><td align="center" valign="middle" rowspan="1" colspan="1">63.1 &#x000b1; 10.3</td><td align="center" valign="middle" rowspan="1" colspan="1">58.8</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" rowspan="1" colspan="1">PEA 27.5%</td><td align="center" valign="middle" rowspan="1" colspan="1">16 weeks</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Suntharalingam et al. [<xref rid="B15-medsci-13-00057" ref-type="bibr">15</xref>]</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">60.0 &#x000b1; 14.4</td><td align="center" valign="middle" rowspan="1" colspan="1">30</td><td align="center" valign="middle" rowspan="1" colspan="1">29.8 &#x000b1; 6.1</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" rowspan="1" colspan="1">PEA 70%</td><td align="center" valign="middle" rowspan="1" colspan="1">12 weeks</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>CHEST-1 [<xref rid="B7-medsci-13-00057" ref-type="bibr">7</xref>]</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">88</td><td align="center" valign="middle" rowspan="1" colspan="1">59 &#x000b1; 13</td><td align="center" valign="middle" rowspan="1" colspan="1">61</td><td align="center" valign="middle" rowspan="1" colspan="1">28 &#x000b1;5</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" rowspan="1" colspan="1">PEA 23%</td><td align="center" valign="middle" rowspan="1" colspan="1">16 weeks</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>MERIT-1 [<xref rid="B8-medsci-13-00057" ref-type="bibr">8</xref>]</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">40</td><td align="center" valign="middle" rowspan="1" colspan="1">56.9 &#x000b1; 13.9</td><td align="center" valign="middle" rowspan="1" colspan="1">63</td><td align="center" valign="middle" rowspan="1" colspan="1">26.2 &#x000b1; 4.0</td><td align="center" valign="middle" rowspan="1" colspan="1">63%</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" rowspan="1" colspan="1">24 weeks</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>AMBER 1 [<xref rid="B16-medsci-13-00057" ref-type="bibr">16</xref>]</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">59.8 &#x000b1; 9</td><td align="center" valign="middle" rowspan="1" colspan="1">63</td><td align="center" valign="middle" rowspan="1" colspan="1">27.1 &#x000b1; 6.8</td><td align="center" valign="middle" rowspan="1" colspan="1">0%</td><td align="center" valign="middle" rowspan="1" colspan="1">0%</td><td align="center" valign="middle" rowspan="1" colspan="1">16 weeks</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Tanabe et al. [<xref rid="B17-medsci-13-00057" ref-type="bibr">17</xref>]</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">60 &#x000b1; 5</td><td align="center" valign="middle" rowspan="1" colspan="1">77.8</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" rowspan="1" colspan="1">55.6%</td><td align="center" valign="middle" rowspan="1" colspan="1">PEA 11.1%</td><td align="center" valign="middle" rowspan="1" colspan="1">17 weeks</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Ogo et al. [<xref rid="B18-medsci-13-00057" ref-type="bibr">18</xref>]</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.3 &#x000b1; 9.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">66.7%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEA 12.8%<break/>BPA 56.4%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 weeks</td></tr></tbody></table><table-wrap-foot><fn><p>BMI: body mass index; BPA: balloon pulmonary angioplasty; N/A: not available; PEA: pulmonary endarterectomy; PH: pulmonary hypertension; SD: standard deviation. Studies included with their references: BENEFiT [<xref rid="B14-medsci-13-00057" ref-type="bibr">14</xref>]; Suntharalingam et al. [<xref rid="B15-medsci-13-00057" ref-type="bibr">15</xref>]; CHEST-1 [<xref rid="B7-medsci-13-00057" ref-type="bibr">7</xref>]; MERIT-1 [<xref rid="B8-medsci-13-00057" ref-type="bibr">8</xref>]; AMBER 1 [<xref rid="B16-medsci-13-00057" ref-type="bibr">16</xref>]; Tanabe et al. [<xref rid="B17-medsci-13-00057" ref-type="bibr">17</xref>]; Ogo et al. [<xref rid="B18-medsci-13-00057" ref-type="bibr">18</xref>].</p></fn></table-wrap-foot></table-wrap></floats-group></article>